The U.S. Chamber submitted comments to the European Commission as it considers revisions and updates to its General Pharmaceuticals Legislation, which is Europe’s attempt to foster innovation, improve the resiliency of the healthcare sector in Europe, bolster supply chain security, and ensure access to innovative medicines across the EU. We encouraged the EU to do a better job of rewarding and prioritizing innovation, guarantee strong IP protections for manufacturers, and preserve open and integrated global supply chains rather than attempting to cut Europe off from the global economy in healthcare. We also focused on the importance of digital health and transatlantic coordination, including for research and pandemic response and recovery.
Recommended
- International
Driving Digital Transformation with Côte d'Ivoire
The U.S. Chamber and U.S private sector partners are at the forefront of driving public-private investment in Côte d'Ivoire.
By Dr. Guevera Yao
- International
Rewriting Kenya's Economic Future
By Abdi Mohamed - International
European Parliament Elections 2024: A Business Perspective
By Marjorie Chorlins
- International
European Parliament Elections: Impacts on U.S. Business
By Marjorie Chorlins - International
The G7 Value Proposition: A Business Perspective
By Suzanne P. Clark
View this online